Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A Multicenter, open-label phase 1/2 study of TYRA 300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 gene alterations (SURF301)
    Meeting Abstract

    Zhang, A.; Boni, V.; Hanson, A.; Mantia, C.; Weickhardt, A.; Yu, E.; Gupta, S.; Robert, M.; Iyer, G.; Millward, M.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed/refractory CLL/SLL: Results from BTK-naïve cohort in the phase 1/2 BRUIN study
    Meeting Abstract

    Wierda, W. G.; Eyre, T. A.; Lech-Maranda, E.; Roeker, L. E.; Patel, M.; Fukuhara, N.; Woyach, J. A.; Brown, J. R.; Patel, K.; Tam, C. S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Pelabresib plus ruxolitinib combination therapy in jak inhibitor-naïve patients with myelofibrosis in the phase 3 MANIFEST-2 study: Preliminary evidence of bone marrow recovery
    Meeting Abstract

    Mascarenhas, J.; Rampal, R. K.; Vannucchi, A. M.; Gupta, V.; Oh, S. T.; Kuykendall, A. T.; Mesa, R.; Kiladjian, J. J.; Talpaz, M.; Kremyanskaya, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Dose-optimization study of 3 starting doses of ponatinib: Long-term results from the OPTIC trial
    Meeting Abstract

    Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • A phase 1 trial of valemetostat in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL)
    Meeting Abstract

    Erba, H. P.; Oluwole, O. O.; Bixby, D.; Rampal, R. K.; Fathi, A. T.; Paliwal, P.; Jin, J.; Inoue, A.; Daver, N.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • A real-world evaluation of risk factors for disease progression in patients with polycythemia vera (PV): An analysis from the prospective observational study of patients with polycythemia vera in US clinical practices (REVEAL)
    Meeting Abstract

    Grunwald, M. R.; Zwicker, J. I.; Gerds, A. T.; Burke, J. M.; Xue, Z.; Crowgey, E. L.; Carl, J.; Feldman, P.; Braunstein, E. M.; Oh, S. T.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC
    Meeting Abstract

    Burns, T. F.; Dragnev, K.; Fujiwara, Y.; Murciano-Goroff, Y. R.; Lee, D. H.; Hollebecque, A.; Koyama, T.; Cassier, P.; Italiano, A.; Heist, R. S.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, randomized, placebo-controlled, double-blind, multicenter trial of Selinexor in maintenance therapy for patients with p53 wild-type, advanced or recurrent endometrial carcinoma
    Meeting Abstract

    Webber, K.; Vergote, I.; Mirza, M. R.; Coleman, R.; Fidalgo, J. A. P.; Monk, B. J.; Valabrega, G.; Slomovitz, B.; Van Gorp, T.; Moore, K.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal or bone metastases in the phase II VISION trial
    Meeting Abstract

    Gasking, S.; Reinmuth, N.; Mazieres, J.; Popat, S.; Paz-Ares, L.; Hook, E.; Hatswell, A.; Vlassak, S.; Johne, A.; Vioix, H.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy of selpercatinib by RET fusion partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 trials
    Meeting Abstract

    Solomon, B.; Drilon, A.; Park, K.; Novello, S.; Nadal, E.; Besse, B.; Peled, N.; Peterson, P.; Barker, S.; Szpurka, A. M.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save